

**510(k) SUMMARY****JUN 30 2014****1.0 Submitter:**

Name: Mr. Francis V  
 Address: Advanced Healthcare Products Sdn Bhd  
 Lot 60 & 61, Lorong Senawang 3/2,  
 Senawang Industrial Estate,  
 70450 Seremban, Negeri Sembilan Darul Khusus,  
 Malaysia.  
 Phone No.: +60 6 678 4188  
 Fax No.: +60 6 678 4727

Date of Summary Prepared: June 27, 2014

**2.0 Name of the device:**

Powder Free Blue Nitrile Patient Examination Glove, Non-Sterile

Common Name: Patient Examination Glove

Classification Name: Patient Examination Gloves (21 CFR 880.6250 product code LZA)

Regulatory Class I

**3.0 Identification of The Legally Marketed Devices that equivalency is claimed:**Dermagrip Ultra Powder Free Blue Nitrile Patient Examination Gloves Non-Sterile  
(and various brandnames)

510(k) : K110979

MDL : D133849

Regulatory Class I

Product Code : LZA

**4.0 Description of The Device:**

| <b>Predicate<br/>K110979</b>   | <b>Current<br/>K132354</b>  |
|--|---|
| Dermagrip Ultra Powder Free Blue Nitrile Patient Examination Gloves Non-Sterile (and various brandnames) meets all the requirements of ASTM standard D6319-10 and FDA 21 CFR 880.6250. | <p>Powder Free Blue Nitrile Patient Examination Glove, Non-Sterile meets all the requirements of ASTM standard D6319-10 and FDA 21 CFR 880.6250.</p> <p>The powder free nitrile examination glove is manufactured from synthetic rubber latex. Inner surface of gloves undergo surface treatment process to produce a smooth surface that assists the user in donning the gloves with ease without using any lubricant such as powder on the glove surface. The glove is ambidextrous; i.e. can be worn on right hand or left hand.</p> |

## 510(k) SUMMARY

### 5.0 Intended Use of the Device:

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

### 6.0 Summary of the Technological Characteristics of the Device:

The Powder Free Blue Nitrile Patient Examination Glove, Non-Sterile are summarized with the following technological characteristics compared to ASTM D6319 or equivalent standards.

| CHARACTERISTICS     | STANDARDS                          | DEVICE PERFORMANCE    |  |
|---------------------|------------------------------------|-----------------------|--|
|                     |                                    | Predicate<br>K110979  | Current<br>K132354   |
| Dimensions          | ASTM D6319-10                      | Meets                 | Meets<br>Length min 230mm<br>Width min 95±10   |
| Physical Properties | ASTM D6319-10                      | Meets                 | Meets<br><br><b>Before Aging</b><br>Tensile Strength<br>min 14 MPa<br>Ultimate Elongation<br>Min 500%<br><br><b>After Aging</b><br>Tensile Strength min 14<br>MPa<br>Ultimate Elongation<br>Min 400% |
| Thickness           | ASTM D6319-10                      | Meets                 | Meets<br>Finger min 0.05mm<br>Palm min 0.05mm  |
| Powder Free         | ASTM D6124-06<br>(Reapproved 2011) | Meets<br>≤ 2 mg/glove | Meets<br>≤ 2 mg/glove  |

## 510(k) SUMMARY

| CHARACTERISTICS     | STANDARDS   | DEVICE PERFORMANCE   |   |
|---------------------|---|--|---|
|                     |   | Predicate<br>K110979   | Current<br>K132354  |
| Biocompatibility    | Primary Skin Irritation - ISO 10993-10:2010(E) & Consumer Product Safety Commission, Title 16, Chapter II, Part 1500      | Passes<br>(Not a primary skin irritant)<br>There was no erythema or oedema noted on abraded or non-abraded sites at 24±1 hours and 72±1 hours. The Primary Irritation Index (PII) of test material was "0".  | Passes<br>(Not a primary skin irritant)<br>There was no erythema or oedema noted on abraded or non-abraded sites at 24±1 hours and 72±1 hours. The Primary Irritation Index (PII) of test material was "0".             |
|                     | Dermal Sensitization - ISO 10993-10:2010(E) & Consumer Product Safety Commission, Title 16, Chapter II, Part 1500.3(c)(4) | Passes<br>(Not a contact sensitizer)<br>There was no positive allergic reaction observed during the challenge phase (at 0±2, 24±2 hours and 48±2 hours) in animals treated with the test material and negative control.  | Passes<br>(Not a contact sensitizer)<br>There was no positive allergic reaction observed during the challenge phase (at 0±2, 24±2 hours and 48±2 hours) in animals treated with the test material and negative control. |
| Watertight (1000ml) | ASTM D5151-06 (Reapproved 2011)   | Passes   | Passes<br>AQL 2.5   |
| Intended Use        | -   | The powder free examination glove is a specialty medical glove which is a disposable device intended for medical purposes that is worn on the examiner's hand or forefinger to prevent contamination between examiner and patient bodily fluids, waste or environment. | A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.                                   |

## 510(k) SUMMARY

| CHARACTERISTICS | STANDARDS                                | DEVICE PERFORMANCE                      |  |
|-----------------|--|---|--|
|                 |  | Predicate<br>K110979                    | Current<br>K132354   |
| Material        | ASTM D6319-10                            | Nitrile                                 | Nitrile<br>Sulphur<br>Zinc Oxide<br>Zinc<br>Dibutyldithiocarbamate (ZDBC)<br>Zinc<br>Diethyldithiocarbamate (ZDEC)<br>Phenolic Antioxidant<br>Titanium Dioxide<br>Blue Pigment |
| Color           | -  | Blue                                    | Blue   |
| Texture         | -  | Finger textured                         | Finger textured  |
| Size            | Medical Glove Guidance Manual - Labeling | Small<br>Medium<br>Large<br>Extra Large | Extra Small<br>Small<br>Medium<br>Large<br>Extra Large   |
| Single Use      | Medical Glove Guidance Manual - Labeling | Single use                              | Single use   |
| Manufacturer(s) | -  | Advance Medical Products Sdn Bhd        | Advanced Healthcare Products Sdn Bhd   |

### 7.0 Substantial Equivalent Based on Assessment of Non-Clinical Performance Data

The performance test data of the non-clinical tests that support a determination of substantial equivalence is the same as mentioned immediately above (ASTM Requirements).

### 8.0 Substantial Equivalent Based on Assessment of Clinical Performance Data

Not applicable - Clinical data is not needed for gloves or for most devices cleared by the 510(k) process.

## **510(k) SUMMARY**

---

### **9.0 Conclusion**

The conclusions drawn from the nonclinical and clinical tests that demonstrate that the device is as safe, as effective, and performs as well as or better than the legally marketed device.

Powder Free Blue Nitrile Patient Examination Glove, Non-Sterile will perform according to the gloves performance standards such as ASTM standards, and FDA requirements for water leak test on pinhole AQL. Consequently, the device is substantially equivalent to currently marketed devices.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

June 30, 2014

Advanced Healthcare Products Sdn Bhd  
Mr. Francis V  
Operations Manager  
Lot 60 & 61, Lorong Senawang 3/2  
Senawang Industrial Estate  
70450 Seremban, Negeri Sembilan  
Darul Khusus, MALAYSIA

Re: K132354  
Trade/Device Name: Powder Free Blue Nitrile Patient Examination Gloves, Non-Sterile  
Regulation Number: 21 CFR 880.6250  
Regulation Name: Patient Examination Gloves  
Regulatory Class: I  
Product Code: LZA  
Dated: May 20, 2014  
Received: May 22, 2014

Dear Mr. Francis V:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the [Federal Register](#).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

*Tejasvri Purohit-Sheth, M.D.*

Tejasvri Purohit-Sheth, M.D.  
Clinical Deputy Director  
DAGRID/ODE/CDRH FOR

Erin I. Keith, M.S.  
Director  
Division of Anesthesiology, General Hospital,  
Respiratory, Infection Control and  
Dental Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**Indications for Use**

510(k) Number (if known)  
K132354

Device Name  
Powder Free Blue Nitrile Patient Examination Glove Non-Sterile

*Indications for Use (Describe)*

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hand or finger to prevent contamination between patient and examiner.

Type of Use (Select one or both, as applicable)

- Prescription Use (Part 21 CFR 801 Subpart D)       Over-The-Counter Use (21 CFR 801 Subpart C)

**PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON A SEPARATE PAGE IF NEEDED.**

**FOR FDA USE ONLY**

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

**Sreekanth Gutala -S**

Digitally signed by Sreekanth Gutala -S  
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA,  
ou=People, 0.9.2342.19200300.100.1.1=2000540490,  
cn=Sreekanth Gutala -S  
Date: 2014.06.23 13:54:11 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRAStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*